The percutaneous coronary intervention (PCI) devices market was valued at USD 9.50 billion in the 2024 base year and is projected to reach USD 10.02 billion in 2025, the start of the forecast period, and USD 16.47 billion by 2034, growing at a CAGR of 5.68% during the forecast period 2025–2034. Demand is driven by rising coronary artery disease prevalence, growing aging and obese populations, and favorable regulatory support. Key players include Abbott, B. Braun, ASAHI INTECC Company Limited, Biosensors International Group, Ltd, Boston Scientific Corporation, BIOTRONIK, Cook, Meril Lifesciences, Cordis, Medtronic PLC, Merit Medical System, and Terumo Corporation.

Coronary Artery Disease Burden Fuels Procedure Volumes

Coronary artery disease is the most common heart disease, caused by plaque developing on the walls of the arteries that carry blood to the heart. Its incidence in high-income countries is increased by faulty lifestyles, high-fat diets, excessive alcohol consumption, and smoking. According to the CDC, one out of four deaths in the U.S. is due to heart disease. In China, cardiovascular disease causes approximately 3 million deaths every year, accounting for 41 percent of total deaths, and in Europe it causes more than half of all deaths. CDC data also show that about 30.3 million people in the U.S. have diabetes, or 9.4% of the population, a risk factor expected to fuel PCI use. This burden sustains the percutaneous coronary intervention (PCI) devices market.

Coronary Stents Dominate Product Revenue

Coronary stents accounted for the majority of product share in 2024, owing to high usage in heart-related procedures, consumer preference toward minimally invasive procedures, and technological advancements. The segment is expected to remain dominant over the study period as manufacturers continue to innovate toward efficient clinical outcomes. The remaining product categories in the report are catheters, guidewires, and accessories, but coronary stents remain the clear revenue anchor for the market.

Read More @ https://www.polarismarketresearch.com/industry-analysis/percutaneous-coronary-intervention-pci-devices-market

Drug-Eluting and Third-Generation Stents Improve Outcomes

Competition is intensifying as the use of drug-eluting stents, improved balloon technologies, and advanced catheters rises. The growing number of FDA approvals and the launch of third-generation stents significantly affect the market, as newer-generation devices have shown fewer side effects and improved clinical outcomes with a lower chance of restenosis. In May 2024, Abbott announced the launch of its XIENCE Sierra everolimus-eluting stent system in India, illustrating how manufacturers are extending advanced products into high-volume markets.

Minimally Invasive Procedures and Hospital Adoption

The rapid shift toward minimally invasive procedures such as PCI is gaining prominence among physicians treating coronary conditions. By end use, hospitals held the largest share in 2024, owing to higher patient admissions, trained professionals, and advanced diagnostic and therapeutic systems that support minimally invasive procedures. Reimbursement tie-ups with Medicare and Medicaid also increase hospital utilization. Artificial intelligence is adding value by improving the detection of coronary blockages, guiding stent selection and placement, and reducing procedure time through real-time guidance.

Regional Outlook for the Percutaneous Coronary Intervention (PCI) Devices Market

North America accounted for more than 34.23% of the global market in 2024, with the U.S. and Canada as major contributors, and the region is the largest revenue contributor, followed by Europe and Asia Pacific, with players focusing on R&D to design novel products for physicians. Asia Pacific is projected to grow at the fastest rate, with Japan, India, South Korea, and China as the top three revenue generators, supported by diabetes, obesity, sedentary lifestyles, and growing awareness of PCI procedures. Rapid urbanization and rising disposable income in developing countries are changing lifestyles, including smoking and alcohol use, and raising cardiac risk.

Challenges and Outlook

The high cost of devices may hamper growth, and complications during cardiac catheterization, including bleeding, infection, and pain at the insertion site, remain challenges. Even so, the market is projected to remain highly dynamic as hospitals and clinics increase adoption of PCI procedures, and the rise in chronic conditions globally is creating a lucrative market opportunity.

More Trending Latest Reports By Polaris Market Research:

understanding-paper-bags-and-their-role-in-eco-friendly-packaging

offshore-wind-energy-market

amoled-display-market

data-center-coolant-distribution-units-market

robot-pharmacies-dispensing-technology-market-and-adoption-rates

pea-protein-market

commercial-uav-market

sustainable-aviation-fuel-market

education-technology-saas-tools-market